⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 23, 2025Open Access

Supplementary Figure S4 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

Michelle Choe Danielle Kirkey Isabel Lira Grace Hawkins Melia Blankenfeld Sarah J. Menashe Rhonda E. Ries Brianna Wrightson Christina Root Cyd N. McKay Jack H. Peplinski Raisa Glabman Lara E. Davis Sanjay V. Malhotra Richard Görlick Elizabeth T. Loggers Soheil Meshinchi

View Full Paper

Ask AI

Bookmark

Share

Key Points

Folate receptor-α CAR T cells demonstrate highly efficient antitumor activity against osteosarcoma, outperforming controls.
The preclinical evaluation reveals that the therapeutic approach is particularly effective when targeting osteosarcoma cells.
Observational analysis across supplemented figures indicates clear benefits of CAR T cell application against tumor models.
This finding highlights a potential shift in treatment strategies for osteosarcoma cases, suggesting further clinical evaluation is warranted.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Evaluation shows enhanced antitumor activity in osteosarcoma using folate receptor-α CAR T cells, indicating a promising therapeutic approach.

Abstract

Supplementary Figure S4. FOLR1-negative control, Kasumi-1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Choe et al. (2025) studied this question.

synapsesocial.com/papers/68d6d8978b2b6861e4c3eb8c https://doi.org/10.1158/2767-9764.30186170

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
2Supplementary Figure S2 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
3Supplementary Figure S5 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
4Supplementary Figure S1 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
5Figure 5 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025

More related papers

Figure 2 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
Figure 6 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025
Figure 3 from Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma2025